| Literature DB >> 10625337 |
Abstract
It has been demonstrated that abnormal levels of PMP22 expression due to altered gene dosage in CMT1A neuropathy alters Schwann cell growth and differentiation. On the other hand, disease-related missense mutations within transmembrane domains of PMP22 disturb intracellular protein trafficking leading to accumulation of the mutant protein in the endoplasmic reticulum/Golgi compartment. Further, the recently reported association of PMP22 and P0 in peripheral myelin sheds new light on the almost identical phenotypes of CMT1A and CMT1B giving rise to a unifying hypothesis on disease mechanism. Copyright 2000 Wiley-Liss, Inc.Entities:
Mesh:
Substances:
Year: 2000 PMID: 10625337 DOI: 10.1002/(sici)1098-1136(20000115)29:2<182::aid-glia12>3.3.co;2-b
Source DB: PubMed Journal: Glia ISSN: 0894-1491 Impact factor: 7.452